LIfT BioSciences Revenue and Competitors

LIfT Biosciences Ltd is a Biotech start-up bringing a 1st in class Immuno-Oncology Cell Therapy to market that builds on 18 years of ground breaking research into innate cancer immunity and Leukocyte Infusion Therapy (LIfT). LIfT as a medical procedure has already proven to be curative in mice and with promising human data in an FDA approved small proof-of-concept study showing 40-80% tumour necrosis. In October 2017, LIfT BioSciences stunned the world as they produced N-LIfT: ‘The World’s First Ever Neutrophils Ex-vivo from stem cells to Demonstrate Super (selective) Cancer Killing Ability’, and was given first-in-class status by the EMA as an ATMP. N-LIfT is a therapeutic platform that overcomes significant commercial and medical barriers to bringing LIfT to market, transforming a potentially effective but unscalable medical procedure into a potentially scalable and patented product that safely and consistently destroys solid tumours that other therapies can not. Our vision is to develop the world’s first cell bank of ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for all solid tumours, with an initial focus on rare tumours such as NSCLC, liver, ST sarcoma & pancreatic cancer. We are now seeking syndicate partners for our Series A POC Clinical Trial, and co-development partners for commercialisation.